The genitourinary drugs market is expected to grow at a CAGR of 2.9% during the forecast period.
Initially, COVID-19 impacted the studied market owing to cancellations of elective procedures, including genitourinary tract infection treatments. Also, COVID-19 infection had been reported to worsen the symptoms of people with genitourinary disorders. For instance, according to an article published in the Asian Journal of Urology in July 2021, coronaviruses could cause urological symptoms when they infect the genitourinary system. COVID-19 was responsible for genitourinary organ dysfunction and damage. Patients with COVID-19 were found to have kidney impairment in several studies. Some research studies indicated that COVID-19 infection poses the greatest threat to the respiratory, digestive, and reproductive systems. Therefore, the genitourinary market was significantly impacted by COVID-19 in its initial phase. However, post-pandemic, the market started to recover since the restrictions were lifted and elective procedures resumed worldwide. The market is expected to gain pace during the forecast period owing to rising research and development activities for innovation in genitourinary drugs.
The high burden of genitourinary disorders is expected to create opportunities for market players’ product innovation and launches which is expected to propel market growth. For instance, as per the report published by the World Health Organization in November 2021, more than 1.0 million sexually transmitted infections are acquired globally and most of them are asymptomatic. Sexually transmitted infections (STIs) are associated with genitourinary complications which are projected to propel the demand for developing a genitourinary drug for the effective treatment of such diseases, thereby fueling the growth of the market.
Furthermore, the high prevalence of urinary tract infections and urinary incontinence is also contributing to the market growth. For instance, according to a Statpearls article updated in August 2022, it is estimated that around 423 million people (20 years and older) worldwide experience some form of urinary incontinence. The high burden of urinary incontinence globally is expected to propel the market growth.
Additionally, increasing investments in research and developments (R&D) activities for developing novel molecules for treating genitourinary diseases, and an increasing number of pipeline drugs are expected to drive the market during the forecast period. For instance, in February 2022, Asieris Pharmaceuticals received the clinical trial application (CTA) approval for Hexvix, a drug for the diagnosis of bladder cancer, from the National Medical Products Administration (NMPA) of China.
However, increasing counterfeit drugs and a lack of awareness about infections and treatment medications are expected to restrain the genitourinary drug market.
According to a WHO March 2022 update, an estimated 491 million people worldwide aged 15 to 49 (13%) have herpes simplex virus (HSV)-2 infection annually. According to the same source, an estimated 3.7 billion people under 50 (67%) have HSV-1 infection globally. Also, according to a CDC 2021 update, there were an estimated 572 thousand new genital herpes infections in the United States in a single year in 2021. HSV-2 infection is more common among women than among men. The high burden of this disease is expected to propel the drug demand to meet the unmet treatment requirements, which are expected to expedite the segment's growth during the forecast period.
The strategic initiatives adopted by market players for the development of advanced genital herpes drugs are expected to boost the segment's growth. For instance, in July 2021, AiCuris Anti-infective Cures AG initiated Phase III development that will assess orally administered pritelivir for the treatment of drug-resistant mucocutaneous herpes simplex virus (HSV) infections in the immunocompromised. The rising clinical trials are expected to boost segment growth during the forecast period.
Moreover, the high R&D investments by the government and private entities in the STIs are further expected to have a significant impact on the market. For instance, as per the National Center for Health Statistics (NCHS), the investment for sexually transmitted infection research in the United States in 2021 was USD 404 million. More research is expected to spur the launch of new products in the segment propelling the market growth.
According to an article published in the Canadian Journal of Kidney Health and Disease in April 2022, glomerulonephritis (GN) is a major cause of kidney failure and accounts for 20% of incident cases of end-stage kidney disease (ESKD) in Canada annually.
Furthermore, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2021, in the United States, approximately 30 million men had erectile dysfunction (ED). Additionally, a research study published in Canadian Urology Association Journal in October 2021 stated that erectile dysfunction is highly prevalent in Canada. The study also reported that approximately 40% of men in their 40s experienced ED of varying degrees of severity, and the prevalence of ED increases by about 10% per decade. Thus, the region's high burden of genitourinary diseases will increase the demand for drugs to treat such conditions, thereby boosting market growth.
Additionally, the research and development of novel antibiotics for urinary tract infections are expected to aid in market growth. For instance, in April 2022, the FDA approved the supplemental New Drug Applications (sNDAs) for Zerbaxa (ceftolozane and tazobactam) to include the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), including pyelonephritis, in pediatric patients (birth to less than 18 years old). Thus, the approvals for various drugs used to treat genitourinary conditions in different age groups are expected to boost the market in the region over the forecast period.
This product will be delivered within 2 business days.
Initially, COVID-19 impacted the studied market owing to cancellations of elective procedures, including genitourinary tract infection treatments. Also, COVID-19 infection had been reported to worsen the symptoms of people with genitourinary disorders. For instance, according to an article published in the Asian Journal of Urology in July 2021, coronaviruses could cause urological symptoms when they infect the genitourinary system. COVID-19 was responsible for genitourinary organ dysfunction and damage. Patients with COVID-19 were found to have kidney impairment in several studies. Some research studies indicated that COVID-19 infection poses the greatest threat to the respiratory, digestive, and reproductive systems. Therefore, the genitourinary market was significantly impacted by COVID-19 in its initial phase. However, post-pandemic, the market started to recover since the restrictions were lifted and elective procedures resumed worldwide. The market is expected to gain pace during the forecast period owing to rising research and development activities for innovation in genitourinary drugs.
The high burden of genitourinary disorders is expected to create opportunities for market players’ product innovation and launches which is expected to propel market growth. For instance, as per the report published by the World Health Organization in November 2021, more than 1.0 million sexually transmitted infections are acquired globally and most of them are asymptomatic. Sexually transmitted infections (STIs) are associated with genitourinary complications which are projected to propel the demand for developing a genitourinary drug for the effective treatment of such diseases, thereby fueling the growth of the market.
Furthermore, the high prevalence of urinary tract infections and urinary incontinence is also contributing to the market growth. For instance, according to a Statpearls article updated in August 2022, it is estimated that around 423 million people (20 years and older) worldwide experience some form of urinary incontinence. The high burden of urinary incontinence globally is expected to propel the market growth.
Additionally, increasing investments in research and developments (R&D) activities for developing novel molecules for treating genitourinary diseases, and an increasing number of pipeline drugs are expected to drive the market during the forecast period. For instance, in February 2022, Asieris Pharmaceuticals received the clinical trial application (CTA) approval for Hexvix, a drug for the diagnosis of bladder cancer, from the National Medical Products Administration (NMPA) of China.
However, increasing counterfeit drugs and a lack of awareness about infections and treatment medications are expected to restrain the genitourinary drug market.
Genitourinary Drugs Market Trends
Genital Herpes is Expected to Hold a Significant Market Share Over the Forecast Period
Genital herpes is a sexually transmitted infection that can cause blisters and open sores (lesions) in the genital area but can also be asymptomatic. Herpes simplex virus II is the cause of most cases of genital herpes.According to a WHO March 2022 update, an estimated 491 million people worldwide aged 15 to 49 (13%) have herpes simplex virus (HSV)-2 infection annually. According to the same source, an estimated 3.7 billion people under 50 (67%) have HSV-1 infection globally. Also, according to a CDC 2021 update, there were an estimated 572 thousand new genital herpes infections in the United States in a single year in 2021. HSV-2 infection is more common among women than among men. The high burden of this disease is expected to propel the drug demand to meet the unmet treatment requirements, which are expected to expedite the segment's growth during the forecast period.
The strategic initiatives adopted by market players for the development of advanced genital herpes drugs are expected to boost the segment's growth. For instance, in July 2021, AiCuris Anti-infective Cures AG initiated Phase III development that will assess orally administered pritelivir for the treatment of drug-resistant mucocutaneous herpes simplex virus (HSV) infections in the immunocompromised. The rising clinical trials are expected to boost segment growth during the forecast period.
Moreover, the high R&D investments by the government and private entities in the STIs are further expected to have a significant impact on the market. For instance, as per the National Center for Health Statistics (NCHS), the investment for sexually transmitted infection research in the United States in 2021 was USD 404 million. More research is expected to spur the launch of new products in the segment propelling the market growth.
North America is Expected to Hold a Significant Market Share Over The Forecast Period
North America is expected to hold a significant share of the genitourinary drugs market due to the high prevalence of genitourinary diseases, greater awareness, and the presence of robust healthcare infrastructure in the region.According to an article published in the Canadian Journal of Kidney Health and Disease in April 2022, glomerulonephritis (GN) is a major cause of kidney failure and accounts for 20% of incident cases of end-stage kidney disease (ESKD) in Canada annually.
Furthermore, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2021, in the United States, approximately 30 million men had erectile dysfunction (ED). Additionally, a research study published in Canadian Urology Association Journal in October 2021 stated that erectile dysfunction is highly prevalent in Canada. The study also reported that approximately 40% of men in their 40s experienced ED of varying degrees of severity, and the prevalence of ED increases by about 10% per decade. Thus, the region's high burden of genitourinary diseases will increase the demand for drugs to treat such conditions, thereby boosting market growth.
Additionally, the research and development of novel antibiotics for urinary tract infections are expected to aid in market growth. For instance, in April 2022, the FDA approved the supplemental New Drug Applications (sNDAs) for Zerbaxa (ceftolozane and tazobactam) to include the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), including pyelonephritis, in pediatric patients (birth to less than 18 years old). Thus, the approvals for various drugs used to treat genitourinary conditions in different age groups are expected to boost the market in the region over the forecast period.
Genitourinary Drugs Market Competitor Analysis
The genitourinary drugs market is moderately competitive in nature. Major market players are investing high capital in R&D and adopting many strategies, such as new product launches and developments, geographical expansions, collaborations, and acquisitions, to strengthen their market position in the global genitourinary drugs market. Some key market players include Merck and Co. Inc., Cipla Inc., Pfizer, Allergen, and Melinta Therapeutics Inc, among others.Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Cipla Inc.
- Melinta Therapeutics Inc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd
- Camber Pharmaceuticals, Inc.
- Viatris Inc.
Methodology
LOADING...
